Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology https://t.co/SBFbA40cWu https://t.co/cvbtr2EcJD

• Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology | RheumNow

Watch: Lupus Nephritis Therapy Paradigm Shift Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/m8SgtnVd95 https://t.co/cSexK2PCb5

• Lupus Nephritis Therapy Paradigm Shift | RheumNow

IV Secukinumab for AxSpa The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. https://t.co/JhOvPIXOMN https://t.co/GoV62NjSmf

• IV Secukinumab for AxSpa | RheumNow

How early is early in psoriatic arthritis? Is there a window of opportunity for treatment in PsA to ensure optimal outcomes? https://t.co/VkfQZpbtKA https://t.co/o2Vf9vRo9s

• How early is early in psoriatic arthritis? | RheumNow

Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions https://t.co/fRAkAQ3tw8 https://t.co/Rs8ODYns2t

• Cancer and TNF inhibitors | RheumNow

Watch: SpA Insights: New Therapies https://t.co/fkFYpEnDoX https://t.co/bcVJfl2un2

• SpA Insights: New Therapies | RheumNow

#ACRbest Abstracts – Day 2 Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNows #ACRbest abstract reports from Monday, 11/13 at #ACR23. https://t.co/qc1PxBKmow https://t.co/leaXyuS2UF

• #ACRbest Abstracts – Day 2 | RheumNow

Lupus Topic Panel Featuring panelists Dr. Kathryn Dao, Eric Dein and Sheila Reyes, discussing the best and most interesting lupus studies presented at #ACR23. https://t.co/4lZmEBH8or https://t.co/L1ZTNeMFWr

• Lupus Topic Panel | RheumNow

Methotrexate: shall we split up? Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. https://t.co/yxvI9Q0B9m https://t.co/MxPQ4DAGsj

• Methotrexate: shall we split up? | RheumNow

Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases Pregnant women with ARDs and APS face significantly increased risks of CVEs. This increased risk is often attributed to ARDs, its medications or comorbidities associated with it. https://t.co/A2Keo8fH4p https://t.co/oHIYNNlzUU

• Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases | RheumNow

#ACR23 BEST Abstracts from San Diego – Day 1 From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from 11/12/23. You can spot these on Twitter by looking for the (#ACRbest) hashtag. https://t.co/hmSNMFuwAY https://t.co/1X89oE8Iet

• #ACR BEST Abstracts from San Diego – Day 1 | RheumNow

Will CAR T Cells also treat RA? Dr. Jonathan Kay reports on abstract 0424 from #ACR23. https://t.co/shb8tpDut4 https://t.co/xLn36Yg9fn

• Will CAR T Cells also treat RA? | RheumNow

RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? Click here to answer: https://t.co/zevKhcDPjz

• SPONDYLOARTHRITIS (SpA) PATIENTS (PsA, AS, and nr-axSpA) | RheumNow

Watch: Ultrasound for PsA Stratification: Are We There Yet? Dr. Aurelie Najm reports live from #ACR23 https://t.co/TeeBHl2LlU https://t.co/ObFtaJsTWp

• Ultrasound for PsA Stratification: Are We There Yet? | RheumNow